Nanovectors to Prevent Placental Passage of Tocolytic Agents

Status unconfirmed

Conditions studied: Preterm Labor

In brief

The purpose of the study is to find out whether indomethacin encapsulated within a nanovector can stop contractions in pregnant human uterine tissue. Preterm delivery is a major contributor to newborn deaths. The treatment of preterm labor includes medications that stop contractions within the uterus, or womb. Indomethacin is effective in stopping uterine contractions, but crosses the placenta to the unborn baby causing problems for the baby. Nanovectors are used to direct the delivery of medications. If indomethacin can be delivered directly to the uterus using a nanovector, it may be an ideal medication to treat preterm labor. We hypothesize that nanovectors loaded with indomethacin will reduce uterine contractions.

Key facts

Study ID

NCT02199756

Run by

The University of Texas Health Science Center, Houston

People needed

24

Starts

2014-07-01

Expected to finish

2019-07-01

Last updated by the study team

2018-11-02

Who can join

Age: 18 and older, up to 49. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Pregnant women undergoing elective cesarean section who are greater than 37 weeks

You may not qualify if…

• Known infection

Where it is running

• Memorial Hermann Hospital Texas Medical Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.